Funder: National Institutes of Health
Due Dates: February 16, 2025 (New) | March 16, 2025 (Renewal/Resubmission/Revision) | May 8, 2025 (Expiration)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; 2-year project period.
Summary: Supports preclinical research on how radiopharmaceutical therapy agents affect cancer biology, normal tissue, and the tumor microenvironment to inform future clinical trials.
Key Information: Clinical trials are not allowed; projects must include experimental testing of radionuclide-based agents.